1355026-60-6 Usage
Uses
Used in Neurodegenerative Disease Treatment:
CYM 50260 is used as a therapeutic agent for neurodegenerative diseases such as Alzheimer's and Parkinson's. It modulates synaptic transmission and plasticity, potentially slowing down the progression of these diseases and improving the quality of life for patients.
Used in Mood Disorder Treatment:
CYM 50260 is used as a mood stabilizer for disorders such as depression and anxiety. By targeting mGluR1 and mGluR5 receptors, it may help regulate mood and alleviate symptoms associated with these conditions.
Used in Cognitive Enhancement:
CYM 50260 is used as a cognitive enhancer to improve memory, learning, and overall cognitive function. Its action on mGluR1 and mGluR5 receptors may promote neuroplasticity and support the health of neural circuits involved in cognitive processes.
Used in Pharmaceutical Development:
CYM 50260 is used as a lead compound in the development of novel medications targeting group I mGluR agonism. Its selectivity and potency make it a valuable tool for designing drugs with potential applications in various neurological and psychiatric conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1355026-60-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,5,0,2 and 6 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1355026-60:
(9*1)+(8*3)+(7*5)+(6*5)+(5*0)+(4*2)+(3*6)+(2*6)+(1*0)=136
136 % 10 = 6
So 1355026-60-6 is a valid CAS Registry Number.
1355026-60-6Relevant articles and documents
Discovery, design and synthesis of novel potent and selective sphingosine-1-phosphate 4 receptor (S1P4-R) agonists
Guerrero, Miguel,Urbano, Mariangela,Zhao, Jian,Crisp, Melissa,Chase, Peter,Hodder, Peter,Schaeffer, Marie-Therese,Brown, Steven,Rosen, Hugh,Roberts, Edward
, p. 537 - 542 (2012/02/04)
High affinity and selective small molecule agonists of the S1P4 receptor (S1P4-R) may have significant therapeutic utility in diverse disease areas including autoimmune diseases, viral infections and thrombocytopenia. A high-throughput screening (HTS) of the Molecular Libraries-Small Molecule Repository library identified 3-(2-(2,4- dichlorophenoxy)ethoxy)-6-methyl-2-nitropyridine as a moderately potent and selective S1P4-R hit agonist. Design, synthesis and systematic structure-activity relationships study of the HTS-derived hit led to the development of novel potent S1P4-R agonists exquisitely selective over the remaining S1P1-3,5-Rs family members. Remarkably, the molecules herein reported provide novel pharmacological tools to decipher the biological function and assess the therapeutic utility of the S1P4-R.
